- FDA and EMA both approve additional biosimilar versions of Humira® (adalimumab).
- FDA also approves its third biosimilar version of Neupogen® (filgrastim).
- EMA has not approved any new biosimilars in 2022, but has recommended approval of teriparatide biosimilar Sondelbay and the pegfilgrastim biosimilar Stimufend.
As pharmaceutical drug costs attract increasing media attention and political scrutiny, a